Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd2066. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 known ✓ | P41594 | 9/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd2066 SCHEMBL1544607 | 1.00 | GRM5 (0.72) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| Azd2066 SCHEMBL1848325 | 1.00 | GRM5 (0.72) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| Azd2066 SCHEMBL5053440 | 0.99 | GRM5 (0.71) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| Azd2066 SCHEMBL4328931 | 0.99 | GRM5 (0.71) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| Azd2066 SCHEMBL4337705 | 0.95 | GRM5 (0.69) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| Azd2066 SCHEMBL29175535 | 0.95 | GRM5 (0.69) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL5054869 | 0.90 | GRM5 (0.70) | GRM5KCNH2ALDH1A1BCHENPC1 | |
| SCHEMBL4323911 | 0.90 | GRM5 (0.70) | GRM5KCNH2ALDH1A1BCHENPC1 | |
| SCHEMBL29582474 | 0.85 | GRM5 (0.66) | GRM5KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL1544738 | 0.84 | KCNH2 (0.73) | GRM5KCNH2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| CN-114599649-B | Compounds for preventing and/or treating excessive fatigue in mammals | 克拉斯·图林 | 2024-07-12 | — | — | CN | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| EP-4007575-A1 | 4-[5-[(RAC)-1-[5-(3-CHLOROPHENYL)-3-ISOXAZOLYL]ETHOXY]-4-METHYL-4H-1,2,4-TRIAZOL-3-YL]PYRIDINE FOR USE IN PREVENTION AND/OR TREATMENT OF SURMENAGE IN A MAMMAL | THULIN, Claes (SE) | 2022-06-08 | — | — | EP | claimed |
| CN-114599649-A | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for the prevention and/or treatment of hyper-fatigue in mammals | 克拉斯·图林 | 2022-06-07 | — | — | CN | claimed |
| CN-114599649-B | Compounds for preventing and/or treating excessive fatigue in mammals | 克拉斯·图林 | 2024-07-12 | — | — | CN | disclosed |
| CN-113811297-B | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for use in the prevention and/or treatment of pain in animals | 克拉斯·图林 | 2024-03-26 | — | — | CN | disclosed |
| EP-4007575-A1 | 4-[5-[(RAC)-1-[5-(3-CHLOROPHENYL)-3-ISOXAZOLYL]ETHOXY]-4-METHYL-4H-1,2,4-TRIAZOL-3-YL]PYRIDINE FOR USE IN PREVENTION AND/OR TREATMENT OF SURMENAGE IN A MAMMAL | THULIN, Claes (SE) | 2022-06-08 | — | — | EP | disclosed |
| CN-114599649-A | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for the prevention and/or treatment of hyper-fatigue in mammals | 克拉斯·图林 | 2022-06-07 | — | — | CN | disclosed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.